Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Transgene Biotek Ltd has filed a letter to BSE confirming it has published its unaudited financial results for the quarter ended December 31, 2025 (Q3 FY26) in two newspapers on February 17, 2026, as required under SEBI's Listing Regulations. The results were advertised in Business Standard (English edition) and Navatelangana (Telugu edition). The filing is a routine compliance submission where the company attaches the newspaper clippings as proof of publication. The letter is signed by Dr. K. Koteswara Rao, Managing Director. The detailed financial numbers for Transgene Biotek are contained in the attached newspaper clippings rather than the body of the letter.
This is a routine regulatory compliance filing with no direct impact on share price or shareholder value. It simply confirms that the company's Q3 FY26 unaudited results have been made publicly available through newspaper publication as mandated by SEBI, ensuring investors have wider access to the financial information.